Adama Innovations Ltd., a spin-out campus company based at TCD in CRANN and Crospon Ltd., a medical device manufacturer based in Galway - have been selected to take up leading roles in the €3million EU FP7 FaBiMed project.
Adama Innovations Ltd., a spin-out campus company based at TCD in CRANN and Crospon Ltd., a medical device manufacturer based in Galway - have been selected to take up leading roles in the €3million EU FP7 FaBiMed project.
The companies will together receive a total of almost €600k in funding from the EU FP7 funding stream, the EU’s main instrument for funding research in Europe. They join several other companies, and research institutes from the UK, Netherlands, Germany, Austria, Portugal and Spain as part of the project.
FaBiMed is a European Commission project that aims to use nanoscience research to develop advanced manufacturing techniques for medical devices. Nanoscience has the potential to vastly improve medical devices resulting in smaller, more sophisticated medical implants, e.g. heart stents, rapid point-of-care diagnostics, and efficient, painless drug delivery.
Adama Innovations Ltd. was spun out as a campus company from TCD by Principal Investigator Professor Graham Cross in 2013. The company uses a simple and cost-efficient process for imprinting patterns at a scale invisible to the human eye on to materials and hard surfaces. Applications for this technology could include anti-counterfeiting technology, labelling or additive manufacturing to improve functionality. As part of FaBiMed, Adama Innovations will examine how this micro-patterning could be used in moulds and coatings for the fabrication of medical devices, increasing their capability and reducing the cost of manufacture.
While it at first look it may appear solely like a bureaucractic metric, in fact Non Disclosure Agreements (NDAs) are an accurate measure of engagement with industry for a University.
While it at first look it may appear solely like a bureaucractic metric, in fact Non Disclosure Agreements (NDAs) are an accurate measure of engagement with industry for a University.
In essence this milestone indicates that since 2008 ,when the Technology Transfer Initiative commenced in TCD, our office has reached a level of interaction with both companies and other research institutions where it was deemed necessary to formally agree to keep certain knowledge confidential. The counterparties to such agreements range from large multinationals such as Google, Intel and Pfizer to SMEs and Irish based start ups.
Prof Nicola Marples and Dr David Kelly of the Zoology department have been making regular visits to Indonesia since 1999, with Operation Wallacea.
Prof Nicola Marples and Dr David Kelly of the Zoology department have been making regular visits to Indonesia since 1999, with Operation Wallacea. What started out as a one-off expedition has developed into a biogeographical study of the birds of SE Sulawesi. In 2010, College signed a Material Transfer Agreement (MTA) with Haluoleo University (UNHALU) in Kendari, Sulawesi, on behalf of David and Nicola. This document allowed the transfer of genetic samples from the Wakatobi islands to College, in order to catalogue the biodiversity of those islands. Shortly afterwards, a PhD student (Sean Kelly) joined the team to investigate the interactions between bird species on the Wakatobi islands. Sean’s work has been considering, behavioural, morphological and genetic data from the islands.
As a result of these investigations, new bird species will be described from the Wakatobi islands. As soon as Nicola and David started to investigate other islands in SE Sulawesi, it became clear that there were big gaps in the knowledge of the birds from this region. Very recently, College has concluded a new MTA with UNHALU which extends the study area to the whole of SE Sulawesi. The new MTA includes all the islands off the SE Sulawesi coast, as well as the mainland. This means that there are now a number of new islands awaiting investigation. Sean is due to finish his PhD next year, but there are lots of islands, birds and ecosystems for future PhD students to investigate.
Ireland’s 7th EU Presidency between January and June 2013 priortised Jobs, Stability and Growth.
Ireland’s 7th EU Presidency between January and June 2013 prioritised Jobs, Stability and Growth. With a strong emphasis on the links between research and enterprise / job-creation Trinity College hosted a number of high level delegations including:
• COREPER is the body responsible for preparing the work of the Council of the European Union which consists of representatives from the Member States at ambassador-level
• EU Council’s Budget Committee
• EU Presidency Press group
Lead by the Dean of Research, Prof Vinny Cahill and the Associate Dean of Research Prof Derek Sullivan, Prof Dan Bradley, Prof Jonathan Coleman, Prof Valeria Nicolosi, Prof Vinny Wade, Dr Jennifer Edmond and Audrey Crosbie gave presentations on their research, their collaborations with industry, their commercialisation success stories to the visiting dignataries highlighting the impact of Trinity’s knowledge transfer activities.
In April five teams were selected to participate in the first year of Trinity’s new Student Start Up Accelerator LaunchBox
In April five teams were selected to participate in the first year of Trinity’s new Student Start Up Accelerator LaunchBox.
The teams have settled in to Regent House in what many have called the most iconic location for a startup incubator in Europe. If you have an interest in student entrepreneurship please feel free to call in for a Nespresso coffee and a chat with the teams at any time. The teams are :
Wifi Guard: Intruder detection using WiFi
Colour Bandit: Colour transfer between images
ChainGuard; Break the Lock, Break the Bike
Food glorious Food: Feed the Waste or Feed the Hungry
The TTO, with the support of the School of Medicine Research Directorate, held an information and networking session at the Trinity Centre for Health Sciences at St. James’ Hospital on the evening of May 23rd.
The TTO, with the support of the School of Medicine Research Directorate, held an information and networking session at the Trinity Centre for Health Sciences at St. James’ Hospital on the evening of May 23rd. The objective of the event was to disseminate information on the supports available to all Researchers affiliated to the Medical School for protecting and commercialising the College’s research outputs.
Researchers from TCD main campus as well as those based at the TCD-affiliated Hospitals (St’ James’ and Tallaght) attended.
Dr. Margaret Woods, TTO Manager, presented an overview of Researcher supports provided by Trinity Research & Innovation (Research Development Office, Contracts Office, Technology Transfer Office & Entrepreneurship) and on the role and procedures of the Technology Transfer Office in IP Identification, Protection and Exploitation. Dr. Gordon Elliott, TTO Case Manager for Translational Biomedical Science, presented a case study on a successfully funded TCD campus company BioCroi Limited based on IP developed by Dr. Tony Davies at TCD Dept of Clinical Medicine. Prof. Gavin Doherty of Trinity School of Computer Science and founder of Silver Cloud Health Ltd shared his experience of commercialising his online therapeutics solutions research.
The seminar was followed by informal networking over refreshments in the foyer of the Durkan Theatre.
Thanks to Prof. Yuri Volkov, Director of Research, School of Medicine; Ms. Noelle Costelloe Research Administrator and Dr. Ann Murphy Technical Manager IMM.
Directors of Research in other schools interested holding a similar event please contact Gordon.Elliott@tcd.ie (Translational Science), John.Whelan@tcd.ie (ICT), Graham.McMullin@tcd.ie (Physical Sciences) or mjwoods@tcd.ie.
The Trinity College spinout company, Trino Therapeutics which is developing a new class of drugs to tackle inflammatory diseases has raised over €9 million to fund clinical trials.
The Trinity College spinout company, Trino Therapeutics which is developing a new class of drugs to tackle inflammatory diseases has raised over €9 million to fund clinical trials.
Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics, announced that it has raised more than €9 million (US $ 12million) in Series A financing from new investors, Fountain Healthcare Partners and founding investor, the Wellcome Trust. Other investors in Trino include Enterprise Ireland and Growcorp. Both the Wellcome Trust and Fountain Healthcare Partners will be represented on the board of directors.
The company is developing PH46A, the lead candidate from a novel, proprietary, class of drugs which was inspired by the indane scaffold molecule derived from a Taiwanese fern. PH46A is a potential first-in-class oral small molecule drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD).
- See more at: TrinoTherapeutics.com
The teams have settled in to Regent House in what many have called the most iconic location for a startup incubator in Europe. If you have an interest in student entrepreneurship please feel free to call in for a Nespresso coffee and a chat with the teams at any time. The teams are :
Wifi Guard: Intruder detection using WiFi
Colour Bandit: Colour transfer between images
ChainGuard; Break the Lock, Break the Bike
Food glorious Food: Feed the Waste or Feed the Hungry
Writing for Tiny: Helping You Find the Words
@TrinityResearch
https://www.facebook.com/trinitytto